Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial

Plasmodium falciparum Apical Membrane Antigen 1 Diversity Covering (PfAMA1-DiCo) candidate vaccine is a formulation of three recombinant variants of AMA1 designed to provide broader protection against parasites with varying AMA1 sequences. In this staggered phase Ia/Ib randomized, double blind trial...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2017-10, Vol.35 (45), p.6218-6227
Hauptverfasser:	Sirima, S.B., Durier, C., Kara, L., Houard, S., Gansane, A., Loulergue, P., Bahuaud, M., Benhamouda, N., Nebié, I., Faber, B., Remarque, E., Launay, O., Ouedraogo, E., Sanou, G., Gueguen, S., Lopez Perez, E., Ammour, K., Kocken, C., Batteux, F., Tartour, E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants Adults Antibodies Antigens Apical membrane antigen 1 Clinical trials Double-blind studies Immunization Immunogenicity Immunoglobulin G Immunoglobulins Malaria Medical research Monkeys & apes Parasites Plasmodium falciparum Proteins Randomization Respiratory syncytial virus Safety Seasons Vaccine trial Vaccines Vector-borne diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!